TargetGTPase KRas [1-169,G12D]/Son of sevenless homolog 1 [564-1049]()
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 1nMAssay Description:Compounds are diluted to a final start concentration of 100 μM and are tested in duplicate. Assay-ready plates (ARPs) are generated using an Acc...More data for this Ligand-Target Pair
TargetGTPase KRas [1-169,G12D]/Son of sevenless homolog 1 [564-1049]()
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 1nMAssay Description:Compounds are diluted to a final start concentration of 100 μM and are tested in duplicate. Assay-ready plates (ARPs) are generated using an Acc...More data for this Ligand-Target Pair
TargetEpidermal growth factor receptor(Homo sapiens (Human))
Boehringer Ingelheim Rcv
Curated by ChEMBL
Boehringer Ingelheim Rcv
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of EGFR (unknown origin)More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-127](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-127](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-127](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:15 μL of compound in 20% DMSO (serial pre-dilutions of compound are done in 100% DMSO) is pipetted to the wells of a white OptiPlate-96 (Perkin ...More data for this Ligand-Target Pair
TargetGTPase KRas [1-169,G12D]/Son of sevenless homolog 1 [564-1049]()
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:Compounds are diluted to a final start concentration of 100 μM and are tested in duplicate. Assay-ready plates (ARPs) are generated using an Acc...More data for this Ligand-Target Pair
TargetGTPase KRas [1-169,G12D]/Son of sevenless homolog 1 [564-1049]()
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:Compounds are diluted to a final start concentration of 100 μM and are tested in duplicate. Assay-ready plates (ARPs) are generated using an Acc...More data for this Ligand-Target Pair
TargetGTPase KRas [1-169,G12D]/Son of sevenless homolog 1 [564-1049]()
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:Compounds are diluted to a final start concentration of 100 μM and are tested in duplicate. Assay-ready plates (ARPs) are generated using an Acc...More data for this Ligand-Target Pair
TargetGTPase KRas [1-169,G12D]/Son of sevenless homolog 1 [564-1049]()
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:Compounds are diluted to a final start concentration of 100 μM and are tested in duplicate. Assay-ready plates (ARPs) are generated using an Acc...More data for this Ligand-Target Pair
TargetGTPase KRas [1-169,G12D]/Son of sevenless homolog 1 [564-1049]()
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:Compounds are diluted to a final start concentration of 100 μM and are tested in duplicate. Assay-ready plates (ARPs) are generated using an Acc...More data for this Ligand-Target Pair
TargetGTPase KRas [1-169,G12D]/Son of sevenless homolog 1 [564-1049]()
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:Compounds are diluted to a final start concentration of 100 μM and are tested in duplicate. Assay-ready plates (ARPs) are generated using an Acc...More data for this Ligand-Target Pair
TargetGTPase KRas [1-169,G12D]/Son of sevenless homolog 1 [564-1049]()
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:Compounds are diluted to a final start concentration of 100 μM and are tested in duplicate. Assay-ready plates (ARPs) are generated using an Acc...More data for this Ligand-Target Pair
TargetGTPase KRas [1-169,G12D]/Son of sevenless homolog 1 [564-1049]()
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:Compounds are diluted to a final start concentration of 100 μM and are tested in duplicate. Assay-ready plates (ARPs) are generated using an Acc...More data for this Ligand-Target Pair
TargetGTPase KRas [1-169,G12D]/Son of sevenless homolog 1 [564-1049]()
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:Compounds are diluted to a final start concentration of 100 μM and are tested in duplicate. Assay-ready plates (ARPs) are generated using an Acc...More data for this Ligand-Target Pair
TargetGTPase KRas [1-169,G12D]/Son of sevenless homolog 1 [564-1049]()
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:Compounds are diluted to a final start concentration of 100 μM and are tested in duplicate. Assay-ready plates (ARPs) are generated using an Acc...More data for this Ligand-Target Pair
TargetGTPase KRas [1-169,G12D]/Son of sevenless homolog 1 [564-1049]()
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:Compounds are diluted to a final start concentration of 100 μM and are tested in duplicate. Assay-ready plates (ARPs) are generated using an Acc...More data for this Ligand-Target Pair
TargetGTPase KRas [1-169,G12D]/Son of sevenless homolog 1 [564-1049]()
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:Compounds are diluted to a final start concentration of 100 μM and are tested in duplicate. Assay-ready plates (ARPs) are generated using an Acc...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair
TargetE3 ubiquitin-protein ligase Mdm2 [23-117](Homo sapiens (Human))
Boehringer Ingelheim International
US Patent
Boehringer Ingelheim International
US Patent
Affinity DataIC50: 2nMAssay Description:This assay is used to determine whether the compounds inhibit the p53-MDM2 interaction and thus restore p53 function.15 μL of compound in 20% DM...More data for this Ligand-Target Pair